ATE405827T1 - Screening-verfahren - Google Patents

Screening-verfahren

Info

Publication number
ATE405827T1
ATE405827T1 AT04773151T AT04773151T ATE405827T1 AT E405827 T1 ATE405827 T1 AT E405827T1 AT 04773151 T AT04773151 T AT 04773151T AT 04773151 T AT04773151 T AT 04773151T AT E405827 T1 ATE405827 T1 AT E405827T1
Authority
AT
Austria
Prior art keywords
screening
protein
salts
cancer
prevention
Prior art date
Application number
AT04773151T
Other languages
English (en)
Inventor
Atsuko Katano
Yoshihiro Takatsu
Hiroyuki Kobayashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE405827T1 publication Critical patent/ATE405827T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT04773151T 2003-09-11 2004-09-09 Screening-verfahren ATE405827T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003320277 2003-09-11

Publications (1)

Publication Number Publication Date
ATE405827T1 true ATE405827T1 (de) 2008-09-15

Family

ID=34308599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04773151T ATE405827T1 (de) 2003-09-11 2004-09-09 Screening-verfahren

Country Status (5)

Country Link
US (1) US7625696B2 (de)
EP (1) EP1666880B1 (de)
AT (1) ATE405827T1 (de)
DE (1) DE602004016006D1 (de)
WO (1) WO2005026728A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8057990B2 (en) * 2005-03-08 2011-11-15 Takeda Pharmaceutical Company Limited Screening method
WO2009033055A1 (en) * 2007-09-06 2009-03-12 Rutgers, The State University Of New Jersey Methods and kits for identification of anti-excitotoxic compounds
EP2389585A2 (de) * 2009-01-22 2011-11-30 Li-Cor, Inc. Einzelmolekül-proteomik mit dynamischen sonden
WO2012014780A1 (ja) * 2010-07-28 2012-02-02 日産自動車株式会社 双極型電極およびそれを用いた双極型二次電池並びに双極型電極の製造方法
US10806711B2 (en) * 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
AU2014244053B2 (en) 2013-03-13 2018-08-30 University Of Cincinnati Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1083909A4 (de) * 1998-06-11 2002-01-02 Smithkline Beecham Corp hCEPR REZEPTOR
US6265147B1 (en) * 1999-12-01 2001-07-24 The Board Of Trustees Of The Leland Stanford Junior University Method of screening for neuroprotective agents

Also Published As

Publication number Publication date
WO2005026728A1 (ja) 2005-03-24
US7625696B2 (en) 2009-12-01
EP1666880B1 (de) 2008-08-20
US20070026457A1 (en) 2007-02-01
EP1666880A1 (de) 2006-06-07
EP1666880A4 (de) 2007-02-21
DE602004016006D1 (de) 2008-10-02

Similar Documents

Publication Publication Date Title
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA200800536A1 (ru) Тканезащитные пептиды и их применения
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
DE60332320D1 (de) Neues screening-verfahren
WO2002057290A8 (en) Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2005039626A3 (en) Use of hydroxylated amino acids for treating diabetes
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DE602004016006D1 (de) Screening-verfahren
ATE486962T1 (de) Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
EA200701852A1 (ru) Производные аминокислот
ATE464564T1 (de) Screening-verfahren
WO2005023186A3 (en) Methods of identifying agents that inhibit the growth of cancer cells
ATE465175T1 (de) Neuer proteinkomplex und anwendungen davon
DE60308166D1 (de) Dipeptidische wachstumshormonsekretionsförderern
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
EP1455186A4 (de) Screening-verfahren
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
EP1801232A4 (de) Verfahren zum screening eines transmembranenzymhemmstoffs
ATE485831T1 (de) Behandlung von neurodegeneration
EP1559721A4 (de) Neue fprl1-liganden und deren verwendung
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties